Baseline patient and CAR-T characteristics
| Study . | Patients, n . | Age . | Prior HSCT n (%) . | Ph+ n, (%) . | Median pre-CAR-T blast, % . | CAR-T construct type . | T-cell origin . | Antigen target . | Median dose . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Median age . | Combined/adult-only . | |||||||||
| Dai et al, 202015 | 6 | 23.5 (17-44) | Combined | 0 | 1 (16.67) | 46.97 | 41BB | Autologous | Bispecific C19/22 | 2 × 106 per kg |
| Dai et al, 201516 | 9 | 35 (15-65) | Combined | 3 (33.33) | 5 (55.56) | 73.44 | 41BB | Autologous/ allogeneic* | CD19 | 4.5 × 106 per kg |
| Frey et al, 202017 | 35 | 34 (21-70) | Adult | 13 (37.14) | 3 (8.57) | NA | 41BB | Autologous | CD19 | Total dose: 5 × 108 |
| Gu et al, 202018 | 20 | 18 (3-52) | Combined | NA | 2 (10) | 35.50 | 41BB | Autologous | CD19 | 5 × 106 per kg |
| Hay et al, 201919 | 53 | 39 (20-76) | Adult | 23 (43.40) | 11 (20.75) | 28 | 41BB | Autologous | CD19 | 2 × 105per kg |
| Hua et al, 202020 | 11 | 28 (12-39) | Combined | 11 (100) | 5 (45.45) | NA | 41BB | Allogeneic | CD19 | 5 × 106per kg |
| Hu et al, 201721 | 15 | 32 (7-57) | Combined | 7 (46.67) | 4 (26.67) | 63.50 | 41BB | Autologous | CD19 | 3.7 × 106per kg |
| Jiang et al, 201922 | 58 | 28 (10-65) | Combined | 3 (5.17) | 7 (12.07) | 12.10 | 41BB | Autologous | CD19 | 1.66 × 106 per kg |
| Li et al, 201823 | 10 | 33 (18-59) | Adult | 1 (10) | 2 (20) | 12.75 | 41BB, CD28† | Autologous | CD19 | 0.62 × 106 per kg |
| Ma et al, 202024 | 9 | 34.1 (16-57) | Combined | 0 | 2 (22.22) | 5.20 | 41BB | Autologous | CD19 | 1 × 106 per kg |
| Ortíz-Maldonado et al, 202025 | 38§ | 24.5 (3-67) | Combined | 33 (86.84) | NA | NA | 41BB | Autologous | CD19 | NA |
| Park et al, 201826 | 53 | 44 (23-64) | Adult | 19 (35.85) | 16 (30.19) | 63 | CD28 | Autologous | CD19 | 3 × 106 per kg |
| Shah et al, 20219 | 55 | 40 (IQR 28-52) | Adult | 23 (42) | 15 (27) | 60 | CD28 | Autologous | CD19 | 1 × 106 per kg |
| Wang et al, 202027 | 23 | 42 (10-67) | Combined | 0 | 7 (30.43) | 40.40 | 41BB | Autologous | CD19 | 1 × 106 per kg |
| Wang et al, 202028 | 51 | 27 (9 to 62) | Combined | 9 (17.65) | 13 (25.49) | 59 | Third generation | Autologous | Sequential CD19 followed by CD22 | CAR19: 2.6 × 106 per kg CAR22: 2.7 × 106 per kg |
| Zhang et al, 202029 | 43 | 24 (4 to 60) | Combined | 43 (100) | 5 (11.63) | NA | 41BB, CD28‡ | Allogeneic | CD19 | 1.76 106 per kg |
| Study . | Patients, n . | Age . | Prior HSCT n (%) . | Ph+ n, (%) . | Median pre-CAR-T blast, % . | CAR-T construct type . | T-cell origin . | Antigen target . | Median dose . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Median age . | Combined/adult-only . | |||||||||
| Dai et al, 202015 | 6 | 23.5 (17-44) | Combined | 0 | 1 (16.67) | 46.97 | 41BB | Autologous | Bispecific C19/22 | 2 × 106 per kg |
| Dai et al, 201516 | 9 | 35 (15-65) | Combined | 3 (33.33) | 5 (55.56) | 73.44 | 41BB | Autologous/ allogeneic* | CD19 | 4.5 × 106 per kg |
| Frey et al, 202017 | 35 | 34 (21-70) | Adult | 13 (37.14) | 3 (8.57) | NA | 41BB | Autologous | CD19 | Total dose: 5 × 108 |
| Gu et al, 202018 | 20 | 18 (3-52) | Combined | NA | 2 (10) | 35.50 | 41BB | Autologous | CD19 | 5 × 106 per kg |
| Hay et al, 201919 | 53 | 39 (20-76) | Adult | 23 (43.40) | 11 (20.75) | 28 | 41BB | Autologous | CD19 | 2 × 105per kg |
| Hua et al, 202020 | 11 | 28 (12-39) | Combined | 11 (100) | 5 (45.45) | NA | 41BB | Allogeneic | CD19 | 5 × 106per kg |
| Hu et al, 201721 | 15 | 32 (7-57) | Combined | 7 (46.67) | 4 (26.67) | 63.50 | 41BB | Autologous | CD19 | 3.7 × 106per kg |
| Jiang et al, 201922 | 58 | 28 (10-65) | Combined | 3 (5.17) | 7 (12.07) | 12.10 | 41BB | Autologous | CD19 | 1.66 × 106 per kg |
| Li et al, 201823 | 10 | 33 (18-59) | Adult | 1 (10) | 2 (20) | 12.75 | 41BB, CD28† | Autologous | CD19 | 0.62 × 106 per kg |
| Ma et al, 202024 | 9 | 34.1 (16-57) | Combined | 0 | 2 (22.22) | 5.20 | 41BB | Autologous | CD19 | 1 × 106 per kg |
| Ortíz-Maldonado et al, 202025 | 38§ | 24.5 (3-67) | Combined | 33 (86.84) | NA | NA | 41BB | Autologous | CD19 | NA |
| Park et al, 201826 | 53 | 44 (23-64) | Adult | 19 (35.85) | 16 (30.19) | 63 | CD28 | Autologous | CD19 | 3 × 106 per kg |
| Shah et al, 20219 | 55 | 40 (IQR 28-52) | Adult | 23 (42) | 15 (27) | 60 | CD28 | Autologous | CD19 | 1 × 106 per kg |
| Wang et al, 202027 | 23 | 42 (10-67) | Combined | 0 | 7 (30.43) | 40.40 | 41BB | Autologous | CD19 | 1 × 106 per kg |
| Wang et al, 202028 | 51 | 27 (9 to 62) | Combined | 9 (17.65) | 13 (25.49) | 59 | Third generation | Autologous | Sequential CD19 followed by CD22 | CAR19: 2.6 × 106 per kg CAR22: 2.7 × 106 per kg |
| Zhang et al, 202029 | 43 | 24 (4 to 60) | Combined | 43 (100) | 5 (11.63) | NA | 41BB, CD28‡ | Allogeneic | CD19 | 1.76 106 per kg |
Seven (77.77%) patients received autologous CAR-T, and 2 (22.22%) received allogeneic CAR-T.
Five (50%) patients received 41BB CAR-T cells and 5 (50%) received CD28 CAR-T cells.
§ Efficacy outcome analysis done for 27 patients who were >18 years, toxicity analysis done for all 38 patients (adult and pediatric) since toxicity data for only adult patients was not available
Twenty-five (58.13%) patients received 41BB CAR T cells, and 18 (41.87%) received CD28 CAR T cells.